Nuveen ESG Mid-Cap Growth ETF
NUMG - ETF AI Analysis
Top Page
Nuveen ESG Mid-Cap Growth ETF (NUMG)
NUMG, the Nuveen ESG Mid-Cap Growth ETF, has a solid overall rating driven largely by strong, well-diversified holdings like Comfort Systems USA, Idexx Laboratories, Keysight Technologies, and Ulta Beauty, all of which show healthy financial performance, positive earnings commentary, and constructive growth outlooks. These strengths are partly offset by weaker spots such as Zscaler and Lumentum, where valuation, profitability, and technical pressures introduce more uncertainty, and the fund’s tilt toward higher-growth, premium-valued names means investors should be comfortable with some volatility and valuation risk.
NUMG vs. SPDR S&P 500 ETF (SPY)
- AUM
- 295.44M
- Region
- North America
- Expense Ratio
- 0.31%
- Beta
- 1.15
- Issuer
- Nuveen
- Inception Date
- Dec 13, 2016
- Dividend Yield
- 0.01%
- Asset Class
- Equity
- Index Tracked
- MSCI Nuveen ESG USA Mid Cap Growth
NUMG Summary
NUMG is the Nuveen ESG Mid-Cap Growth ETF, which follows the MSCI Nuveen ESG USA Mid Cap Growth index. It invests in medium‑sized U.S. companies that are growing quickly and meet strict environmental, social, and governance (ESG) standards. The fund is heavy in technology and health care, with well-known names like Atlassian and Ulta Beauty among its holdings. Someone might invest in NUMG to seek long‑term growth while supporting more responsible business practices. A key risk is that mid-cap growth and tech-focused stocks can be more volatile, so the ETF’s value can go up and down sharply with the market.
How much will it cost me?
NUMG has an annual expense ratio of 0.31%, which means you’ll pay about $3.10 per year for every $1,000 invested. This cost is a bit higher than the average index ETF because NUMG is passively tracking a specialized ESG mid-cap growth index, which requires more targeted screening and research than broad market funds.
What would affect this ETF?
NUMG could benefit from strong growth in U.S. technology and health care companies, as well as increasing investor demand for ESG-focused funds, which supports many of its mid-cap holdings like software, medical, and industrial firms. On the downside, rising interest rates, an economic slowdown that hurts growth and consumer-focused businesses, or changes in ESG regulations and standards could weigh on the fund’s performance and limit the pool of eligible companies.
NUMG Top 10 Holdings
NUMG leans heavily into U.S. mid-cap tech and growth names, with software and networking players like Atlassian, Zscaler, Veeva, and Ciena doing much of the heavy lifting as they ride strong, AI-driven momentum. Keysight and Resmed add steady support from the industrial and health care side, helping smooth out bumps. On the weaker end, Comfort Systems has been losing steam recently, and Roblox remains a wild card with rising engagement but lagging share performance. Overall, the fund is a U.S.-centric, tech-tilted ESG growth story.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 IDXX | Idexx Laboratories | 4.09% | $12.11M | $53.26B | -5.28% | 78Outperform |
 VEEV | Veeva Systems | 3.76% | $11.11M | $49.18B | 4.30% | 66Neutral |
 GWW | WW Grainger | 3.01% | $8.89M | $67.45B | 51.23% | 73Outperform |
 ULTA | Ulta Beauty | 3.00% | $8.89M | $27.57B | 26.46% | 78Outperform |
 RMD | Resmed | 2.96% | $8.75M | $33.10B | -5.75% | 76Outperform |
 LITE | Lumentum Holdings | 2.85% | $8.43M | $48.85B | 124.71% | 61Neutral |
 RBLX | Roblox | 2.70% | $7.97M | $35.28B | -51.32% | 51Neutral |
 LYV | Live Nation Entertainment | 2.61% | $7.73M | $41.29B | 27.20% | 69Neutral |
 SN | SharkNinja, Inc. | 2.61% | $7.73M | $31.42B | 142.60% | 76Outperform |
 KEYS | Keysight Technologies | 2.60% | $7.68M | $46.33B | 47.06% | 77Outperform |
NUMG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For NUMG, the sentiment is Negative. The current price of 42.86 is below the 20-day moving average (MA) of 45.50, below the 50-day MA of 45.97, and below the 200-day MA of 45.28, indicating a bearish trend. The MACD of -0.68 indicates Positive momentum. The RSI at 33.64 is Neutral, neither overbought nor oversold. The STOCH value of 18.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUMG.
NUMG Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| NUMG | $42.86 | $49.00(14.33% Upside) | $295.44M | 0.31% | 69Neutral |
 FNY | $95.55 | $120.24(25.84% Upside) | $529.07M | 0.73% | 67Neutral |
 RFG | $54.53 | $72.54(33.02% Upside) | $297.88M | 0.35% | 73Outperform |
 GLRY | $36.05 | $44.85(24.41% Upside) | $150.11M | 0.80% | 74Outperform |
 FRTY | $20.18 | $25.79(27.80% Upside) | $128.40M | 0.60% | 61Neutral |
 TMFM | $22.20 | $26.92(21.26% Upside) | $110.34M | 0.85% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NUMG | Nuveen ESG Mid-Cap Growth ETF | 42.86 | -5.30 | -11.01% | |
| FNY | First Trust Mid Cap Growth AlphaDEX Fund | 95.55 | 4.24 | 4.65% | |
| RFG | Invesco S&P Midcap 400 Pure Growth ETF | 54.53 | 2.50 | 4.81% | |
| GLRY | Inspire Faithward Mid Cap Momentum ESG ETF | 36.05 | -0.23 | -0.63% | |
| FRTY | Alger Mid Cap 40 ETF | 20.18 | -1.26 | -5.86% | |
| TMFM | Motley Fool Mid-Cap Growth ETF | 22.20 | -1.54 | -6.49% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.